Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma — StellaPhase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.
Trial locations(1 site)
China
Yang Xu, Hangzhou, Zhejiang Age range
18 Years – 80 Years
Last updated January 2026